GPC-3 CAR T CELLS FOR Recurrent GPC-3 Positive Glioblastoma

The body has different ways of fighting infection and disease. No single way seems perfect for fighting cancers. This research study combines two different ways of fighting cancer: antibodies and T cells. Antibodies are types of proteins that protect the body from infectious diseases and possibly cancer. T-cells, also called T lymphocytes, are special infection-fighting blood cells that can kill other cells, including cells infected with viruses and tumor cells. Both antibodies and T cells have been used to treat participants with cancers. They have shown promise, but have not been strong eno

Trial Details

NCT ID
NCT06815432
Phase
PHASE1
Sponsor
Baylor College of Medicine
Status
RECRUITING
Cancer Type
Glioblastoma (GBM) Brain Cancer
Interventions
  • 15.GPC3-CAR T cells
Locations (sample)
  • Houston, Texas, United States|29.76328,-95.36327

Key Eligibility Criteria

  • Diagnosis of GPC3-positive recurrent glioblastoma with previous resection planned for repeat resection.
  • Age ≥18 years
  • Karnofsky score ≥60%
  • Informed consent explained to, understood by and signed by patient/guardian. Patient/guardian given copy of informed consent

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Glioblastoma (GBM) Brain Cancer Trials on Trialify →